48.74
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$47.94
Offen:
$47.27
24-Stunden-Volumen:
1.07M
Relative Volume:
0.46
Marktkapitalisierung:
$7.46B
Einnahmen:
$700.35M
Nettoeinkommen (Verlust:
$461.90M
KGV:
16.98
EPS:
2.8696
Netto-Cashflow:
$-14.19M
1W Leistung:
-2.05%
1M Leistung:
-11.20%
6M Leistung:
+71.02%
1J Leistung:
+75.51%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TGTX
Tg Therapeutics Inc
|
48.74 | 7.58B | 700.35M | 461.90M | -14.19M | 2.8696 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
US High Growth Tech Stocks To Watch: 3 Top Picks - Sahm
TGTX Stock Slips After Earnings – But CEO's $1B Briumvi Outlook Keeps Retail Bullish - Stocktwits
Trading Systems Reacting to (TGTX) Volatility - Stock Traders Daily
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX - marketbeat.com
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Latest Stock News & Headlines - Yahoo Finance
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Stocktwits
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished - AOL.com
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - finance.yahoo.com
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript - AOL.com
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Biotech with Strong Revenue Growth and Substantial Upside Potential - DirectorsTalk Interviews
TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP - marketbeat.com
TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance UK
TG Therapeutics (TGTX) Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed? - Sahm
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
TG Therapeutics Inc (TGTX) Stock News Today - TradingKey
Director gifts 6,050 TG Therapeutics (TGTX) shares to 501(c)(3) - Stock Titan
TGTX Maintained by JP Morgan -- Price Target Raised to $72.00 - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price - marketbeat.com
TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings - simplywall.st
California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Earnings Call Signals BRIUMVI Surge - The Globe and Mail
TG Therapeutics 2026: Revenue $240.34M, EPS $0.05— 10-Q Summary - tradingview.com
TG Therapeutics (NASDAQ: TGTX) grows 2026 revenue to $445 million - Stock Titan
TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co. - MarketBeat
Is TG Therapeutics (TGTX) A Bargain As Higher Guidance Meets A Sharp Pullback? - Yahoo Finance
TG Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
TG Therapeutics (TGTX) Stock May Be Undervalued As Revenue Guidance Rises - Yahoo Finance
TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth - Sahm
TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 OutlookWhat's Changed - finance.yahoo.com
TG Therapeutics: Why I'm Staying Long After The Q2 Selloff (NASDAQ:TGTX) - Seeking Alpha
Why TG Therapeutics (TGTX) Stock Is Down Today - Quiver Quantitative
TG Therapeutics (NASDAQ:TGTX) Trading Down 9% on Disappointing Earnings - MarketBeat
TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance - TG Therapeutics
TG Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: TG Therapeutics Q2 2026 revenue rises, shares fall 5% - Investing.com
TG Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings - Yahoo Finance
TG Therapeutics raises 2026 revenue guidance on Briumvi sales - Investing.com
TG Therapeutics Raises 2026 Outlook Following Strong Briumvi Sales Growth - Yahoo Finance
Weekly Recap: B. Riley raises TG Therapeutics target to $86 and Aug 3 Q2 call - TradingView
TG Therapeutics Q2 Earnings Fall, Revenue Rises; Fiscal 2026 Revenue Outlook Raised - Yahoo Finance
TG Therapeutics reports Q2 2026 revenue ~$240M, raises 2026 BRIUMVI U.S. revenue guidance - TradingView
TG Therapeutics: Q2 Earnings Snapshot - Barchart.com
TG Therapeutics (NASDAQ: TGTX) lifts 2026 BRIUMVI revenue outlook - Stock Titan
TG Therapeutics, Inc. (TGTX) Stock Analysis: 31.52% Potential Upside Beckons Investors - DirectorsTalk Interviews
How Tg Therapeutics Inc. (TGTX) Affects Rotational Strategy Timing - Stock Traders Daily
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):